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Abstract 
 
Introduction 
Melanoma is a malignant tumour derived from neuroectodermal melanoma-
tose cells that primarily involve the skin, referred to as cutaneous melanoma. 
Recently, ipilimumab (Yervoy
®
) was approved for the adjuvant treatment of 
patients with high-risk stage III melanoma by the Food and Drug Admin-
istration (FDA) in the U.S. Ipilimumab is a fully human monoclonal immu-
noglobulin (Ig) G1 antibody that can block the interaction between B7 and 
CTLA-4 proteins and consequently activates a cytotoxic T-lymphocyte-
mediated immune response against cancer cells. 
Methodology  
On 13 March 2017 a literature search was conducted in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Based on the EUnetHTA internal validity for randomised controlled trials, 
the methodological quality of the evidence was conducted to assess the risk 
of bias at the study level. Furthermore, to evaluate the magnitude of clinical-
ly meaningful benefit that can be expected from ipilimumab, the original as 
well as an adapted version of the Magnitude of Clinical Benefit Scale 
(MCBS) developed by the European Society for Medical Oncology (ESMO) 
was used. 
Results of the EORTC 18071 trial 
Between 10 July 2008 and 1 August 2011, 951 patients were randomly as-
signed to receive either ipilimumab (n = 475) or placebo (n = 476). At a 
median follow-up of 5.3 years the primary endpoint, recurrence-free survival 
(RFS) rate at five years, was 40.8% in the ipilimumab group, as compared 
with 30.3% in the placebo group (hazard ratio for recurrence or death, 0.76; 
95% CI, 0.64–0.89; p < 0.001). Moreover, the overall survival (OS) rate and 
the rate of distant metastasis-free survival (DMFS) at five years significantly 
improved in the ipilimumab group compared to the placebo group. Howev-
er, there was a 40.0% difference in grade ≥3 immune-related adverse events 
in the ipilimumab group, and five patients (1.1%) died due to immune-
related adverse events before the start of the maintenance therapy. In total, 
240 of 471 patients (51.0%) discontinued treatment due to an ipilimumab-
induced adverse event. Moreover, no clinically relevant differences in global 
health status scores were observed during or after induction therapy between 
the two treatment groups.  
Conclusion 
Overall, even if the administration of ipilimumab increases the rate of toxic-
ities, no statistically significant differences in health-related quality of life 
scores between the treatment groups have been observed. In fact, ipili-
mumab significantly improved the rates of RFS, OS and DMFS at five years. 
Nevertheless, the identification of predictive biomarkers may be crucial in 
order to further improve response rates and outcomes, and to reduce severe 
adverse events. In addition, ongoing studies remain to be seen in order to 
gain comparable results. Finally, aiming for a reduction of immune therapy 
costs (annual ipilimumab therapy costs: € 435,850.10) may be a crucial step 
in the near future.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organises 
HTA information according to pre-defined generic research questions. Based 
on these generic questions, the following research questions were answered in 
the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is ipilimumab? 
A0022 Who manufactures ipilimumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has ipilimumab received marketing authorisation? 
Health problem and current use 
A0002 What is cutaneous melanoma? 
A0004 What is the natural course of melanoma? 
A0006 What are the consequences of melanoma for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of cutaneous melanoma? 
A0003 What are the known risk factors for melanoma? 
A0024 
How is cutaneous menaloma currently diagnosed according to published guidelines and in 
practice? 
A0025 How is melanoma currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of ipilimumab on mortality? 
D0006 How does ipilimumab affect progression (or recurrence) of cutaneous melanoma? 
D0005 
How does ipilimumab affect symptoms and findings (severity, frequency) of cutaneous 
melanoma? 
D0011 What is the effect of ipilimumab on patients ̕ body functions? 
D0012 What is the effect of ipilimumab on generic health-related quality of life? 
D0013 What is the effect of ipilimumab on disease-specific quality of life? 
Safety 
C0008 How safe is ipilimumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying ipilimumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the use 
of ipilimumab? 
A0021 What is the reimbursement status of ipilimumab? 
  
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Ipilimumab/Yervoy/L01XC11 
 
B0001: What is ipilimumab? 
Ipilimumab is a fully human monoclonal immunoglobulin (Ig) G1 antibody 
that binds to the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). 
Ipilimumab can block the interaction between B7 and CTLA-4 proteins, be-
cause natural immune response in the form of a reaction to cancer cells is 
generated by removing the CTLA-4 inhibitory signal and releasing a brake 
on the immune system. This process leads to a cytotoxic T-lymphocyte 
(CTL)-mediated immune response against cancer cells which results in an 
immune-mediated anti-tumour activity [2-8]. 
The recommended dose of ipilimumab is 10 mg/kg administered intrave-
nously over 90 minutes every three weeks for four times (four doses) as in-
duction therapy followed by 10 mg/kg every 12 weeks for up to three years as 
maintenance therapy or until disease recurrence, unacceptable level of toxic-
ities, major protocol violation or withdrawal of consent [3, 9]. 
 
A0022: Who manufactures ipilimumab? 
Bristol-Myers Squibb 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Ipilimumab is indicated for the adjuvant therapy in patients with high-
risk stage III cutaneous melanoma (CM) after complete regional lymph 
node dissection (CLND) [3, 9, 10]. 
 
 
 
 
 
fully human monoclonal  
Ig G1 antibody against  
the CTLA-4 protein 
 
10 mg/kg every 3 weeks 
for 4 doses, then every 3 
months for up to 3 years 
adjuvant therapy for 
high-risk stage III CM 
Horizon Scanning in Oncology 
8 LBI-HTA | 2017 
4 Current regulatory status 
A0020: For which indications has the technology received marketing author-
isation? 
In March 2011 ipilimumab was approved by the U.S. Food and Drug Ad-
ministration (FDA) for the treatment of unresectable or late-stage (metastat-
ic) melanoma. In October 2015 ipilimumab was additionally approved for 
the adjuvant treatment of patients with high-risk stage III melanoma [9]. 
 
 
In March 2011 ipilimumab was also approved by the European Medicines 
Agency (EMA) for the treatment of unresectable or metastatic melanoma in 
adults who have received prior therapy [11]. However, currently ipilimumab 
does not have a marketing authorisation in Europe for the adjuvant therapy 
of patients with high-risk stage III melanoma. 
 
 
 
5 Burden of disease 
A0002: What is cutaneous melanoma? 
Melanoma is a malignant tumour derived from neuroectodermal melanoma-
tose cells that primarily involve the skin, referred to as CM [12, 13]. Fur-
thermore, melanoma cells can also arise in the eyes, meninges and on vari-
ous mucosal surfaces [14]. There are different subtypes of CM, including 
superficially spreading melanoma (SSM), nodular melanoma (NM), lentigo 
maligna melanoma (LMM) and acral lentiginous melanoma (ALM). In addi-
tion, CM can be categorised based on variations in specific genetic altera-
tions, such as non-chronic sun-damage (non-CSD) melanoma, which in-
cludes the highest proportion of BRAF mutations compared to other sub-
types like chronic sun damage (CSD) melanoma and acral melanoma that 
mostly appear on the soles, palms, and subungual sites [14-18]. 
 
A0004: What is the natural course of melanoma? 
Melanoma can be stratified into different disease stages according to the 
Tumour-Nodes-Metastases (TNM) and the 2009 American Joint Committee 
on Cancer (AJCC) criteria. Stage I to II includes localised disease with no 
evidence of metastases, whereas in stage III evidence for nodal and regional 
disease is given. Stage IV melanoma includes distant-metastasis disease. De-
tailed information about the different stages and sub-stages is illustrated in 
Table 1 [14, 16, 17, 19, 20]. 
 
 
 
2011: FDA approval for 
the treatment of 
metastatic melanoma 
2015: FDA approval for 
adjuvant therapy of 
high-risk stage III 
melanoma 
2011: EMA approval for 
metastatic melanoma; 
no marketing 
authorisation in 
Europe for adjuvant 
therapy of high-risk 
stage III melanoma 
CM: malignant 
tumours derived from 
neuroectodermal 
melanomatose cells 
primarily involved 
in the skin 
 
various subtypes of CM 
stages of melanoma 
according to TNM and 
AJCC criteria 
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Table 1: Disease stages according to TNM and 2009 AJCC criteria  
Stage Primary tumour Lymph nodes  Distant metastases 
0 Tis (melanoma in situ) N0 M0 
IA T1a: ≤1.0 mm, no ulceration AND 
<mitosis rate <1/mm² 
N0 M0 
IB T1b: ≤1.0 mm, no ulceration OR  
<mitosis rate <1/mm² 
T2a: 1.01-2.0 mm no ulceration 
N0 M0 
IIA T2b: 1.01-2.0 mm with ulceration 
T3a: 2.01-4.0 mm no ulceration 
N0 M0 
IIB T3b: 2.01-4.0 mm with ulceration 
T4a: >4 mm no ulceration 
N0 M0 
IIC T4b: >4mm with ulceration N0 M0 
IIIA T1-4a N1a: 1 LN with micro metastases 
N2a: 2-3 LN with micro metasta-
ses 
M0 
IIIB T1-4a N1b: 1 LN with macro metastases 
N2b: 2-3 LN with macro metasta-
ses 
M0 
T1-4b N1a: 1 LN with macro metastases 
T1-4a/b N2a: 2-3 LN with macro metasta-
ses 
N2c: in transit-/satellite lesions no 
LN infestation 
IIIC T1-4b N1b: 1 LN with macro metastases 
N2c: in transit-/satellite lesions no 
LN infestation 
M0 
all T N3: ≥4 LN OR satellite lesions OR 
in transit metastases with LN in-
festation 
IV all T all M1a: skin subcutaneous 
OR LN 
M1b: lung 
M1c: all other organ me-
tastases OR increased 
LDH 
Abbreviations: AJCC = American Joint Committee on Cancer, LDH = lactate dehydrogenase, LN = lymph nodes, M0 = no 
distant metastases, N0 = no metastatic nodes, TNM =Tumour Nodus Metastasis 
 
A0006: What are the consequences of melanoma for the society? 
Melanoma, also known as malignant melanoma, is a type of skin cancer that 
is diagnosed increasingly more often than other malignant diseases [14-16, 
19]. Particularly in western countries, the incidence rate has been increasing 
continuously for young adults since 1980 [16, 19]. One reason for this trend 
might be the climate change. On the one hand, according to the Montreal 
Protocol heralded by Kofi Annan, ozone depletion has led to an increase in 
melanoma and it is still rising. On the other hand, owing to global warming, 
warmer and drier weather encourage people to spend more time outside and 
therefore increase their exposure to ultraviolet (UV) light, which poses a 
high risk factor for melanoma. Consequently, there is an increase in the in-
cidence of melanoma owing to behavioural changes caused by climate 
change [21].  
evidence of increasing 
incidence rate of 
melanoma 
 
 
 
one reason might be 
the climate change 
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A0023: How many people belong to the target population? 
Melanoma is the second most common malign tumour for women and men 
aged between 15 and 39 years in Germany [22]. The age-standardised inci-
dence rate for the European Standard Population (2013) is 21.1 per 100,000 
persons per year. In 2014, 1,794 persons were newly diagnosed with mela-
noma in Austria, of whom approximately 47.9% were women. Moreover, 
around 91.4% of female melanoma patients and 85.2% of male melanoma 
patients (all stages included) are alive at least three years after diagnosis 
[23]. The median age at diagnosis of melanoma is 59 years for women and 66 
years for men. The mortality rate increased by 12.0% (women) and 10.0% 
(men) during the last ten to fifteen years in Austria [19]. Activating muta-
tions of BRAF are found in about 40.0% to 50.0% of patients with melanoma 
[24]. 
 
A0005: What are the symptoms and the burden of cutaneous melanoma? 
Symptoms of CM can be very heterogeneous. Most often they include a mole 
that changes in size, shape or colour, has irregular edges or borders, is 
asymmetrical or ulcerated and that itches, oozes or bleeds [12, 13]. Guidance 
is given with the ABCDE formula, which is used for the description of sus-
picious changes of the skin [13, 19]: 
 A: asymmetry of the lesion 
 B: border irregularities 
 C: colour heterogeneity 
 D: diameter (higher than 5 mm or dynamics of morphological 
changes in the tumour) 
 E: elevation or evolution (elevation of surface above the level of 
surrounding epidermis) 
 
A0003: What are the known risk factors for melanoma? 
Established high risk factors for developing melanoma are multiple clinical-
ly atypical moles or dysplastic nevi, the skin type, a personal history of prior 
melanoma, as well as a positive family history of melanoma, a weak immune 
system and prior radiation treatment or chemotherapy. Additionally, the 
mutation of CDK4 genes and a hereditary retinoblastoma with mutation in 
the RB1 gene is associated with an increased risk of melanoma. Indeed, en-
vironmental factors including excessive sun exposure, UV-based artificial 
tanning and continuous mechanical or chemical irritancy pose high risk fac-
tors for melanoma as well [12, 13, 15-17, 19]. 
 
A0024: How is cutaneous melanoma currently diagnosed according to pub-
lished guidelines and in practice? 
Local diagnosis of CM includes a physical skin exam as well as a dermosco-
py, which can identify differentially pigmented lesions. Currently, dermos-
copy is the standard method for the clinical differential diagnosis of CM and 
for qualifying a lesion for excisional biopsy that can bring further infor-
mation about major risk factors [12]. Moreover, a sentinel lymph node biop-
sy (SLNB) or a fine needle aspiration (FNA) represents options of CM biop-
sies. In particular, a SLNB is important to gather prognostic information 
and identify patients with nodal metastases, who may benefit from immedi-
incidence rate based on 
the European Standard 
Population: 21.1 per 
100,000 persons/year 
 
 
 
median age at diagnosis: 
59 years (women)  
66 years (men) 
main symptoms 
identified with the 
ABCDE formula 
main risk factors: 
clinically atypical moles 
or dysplastic nevi, skin 
type, personal or family 
history, weak immune 
system, exposure to UV 
light and chemicals 
local diagnosis: 
skin exam, 
dermoscopy, 
excisional biopsy,  
SLNB, FNA, 
full body photography, 
CLSM, MTP 
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ate complete lymphadenectomy [18, 25]. Moreover, a full body photography, 
a confocal laser scanning microscopy (CLSM) or a multiphoton laser tomog-
raphy (MPT) can be administered in order to clarify CM moles [15, 19]. 
 
For the molecular diagnosis of CM, a comparative genomic hybridisation 
(CGH) and a fluorescence in situ hybridisation (FISH) can be determined in 
order to detect gene mutations [17]. Especially patients with stage IV CM 
should be screened for BRAF mutations [12, 14, 15]. 
 
Owing to the spread of CM (metastatic disease), a sonography of the lymph 
nodes, X-ray pictures, ultrasound evaluations of the abdomen and the re-
gional lymph nodes, as well as positron emission tomographies (PETs), 
computer tomographies (CTs) or magnetic resonance imaging (MRI) scans 
can be administered. In addition, laboratory tests including complete blood 
counts (CBCs), liver and kidney parameters, electrolytes, alkaline phospha-
tase, serum protein S100B and LDH give further information about the di-
agnosis of CM [12, 14, 16, 17, 19, 20]. 
 
 
 
6 Current treatment 
A0025: How is melanoma currently managed according to published guide-
lines and in practice? 
Generally, melanoma can be treated by surgery, radiotherapy and curative 
adjuvant or palliative therapies. Which treatment strategy is the most suita-
ble for the patient depends on the disease stage (TNM and AJCC criteria), 
the tumour thickness, the patient’s general health, as well as on BRAF and 
C-KIT mutations. 
Treatment strategies of stage ≤IV melanoma with solitary metastases have a 
curative intention. For stage I and IIA melanoma, excision with surgery of 
the primary tumour including a safety distance, depending on the thickness 
of the tumour, constitutes the cornerstone of treatment options [17-19, 25, 
26]. Particularly for patients with positive SLNB, a complete lymph node 
dissection (CLND) is recommended [18, 25]. If surgery is not possible due 
to comorbidity or a cosmetically sensitive tumour location, a topical 
imiquimod or radiation therapy can be administered, especially in lentigo 
maligna melanoma [17, 18]. For high-risk stage IIB or IIIA patients, adju-
vant immune therapy of interferon alpha or anti-CTLA-4 receptor ipili-
mumab is given after completed surgery [17, 19, 24, 27-30]. Furthermore, 
combinations of immune therapies including anti-PD-1/PD-L1 (e.g., pem-
brolizumab or nivolumab) plus ipilimumab are under investigation [28]. 
Commonly, adjuvant treatment strategies for high-risk stage III melanoma 
can be categorised as followed [17, 24, 29, 31]:  
 Local therapy: intralesional injections (talimogene laherparepvec) 
or laser ablation 
 Topical therapies: imiquimod, diphencyprone (DPCP) or radiation 
therapy 
molecular diagnosis: 
CGH, FISH 
disease expansion: 
sonography, 
X-ray pictures, 
ultrasound, 
PETs, CTs, 
MRI scans, 
laboratory tests 
factors for treatment 
decisions 
curative treatment 
options for stage ≤IV 
melanoma with 
solitary metastases 
adjuvant treatment 
options for high-risk 
stage III melanoma 
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 Regional therapy: isolated limb perfusion (ILP) or isolated limb in-
fusion (ILI) for the administration of cytotoxic chemotherapy, im-
mune therapy with ipilimumab or pembrolizumab, ipilimumab in 
combination with chemotherapy, like darcabazine, fotemustine or 
carboplatin/paclitaxel  
In fact, surgery or curative adjuvant therapies can cause treatment disorders. 
Therefore, targeted rehabilitative activities in the somatic and psychosocial 
area are recommended [19]. Due to the high risk of recurrence, follow-up 
treatments including physical examination, blood tests, imaging modalities 
(X-ray, ultrasound, PET/CT, MRI), as well as sonography of the skin and of 
the lymph nodes, are aimed to improve the prognosis and subsequently pre-
vent recurrence through early detection [19]. 
 
 
 
7 Evidence 
A literature search was conducted on 13 March 2017 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “ipilimumab”, “yervoy”, “melanoma”, “adjuvant setting” 
and “adjuvant therapy”. The manufacturer was also contacted and submit-
ted two references (of which one had already been identified by the litera-
ture search). A manual search identified 12 additional references (web doc-
uments and journal articles). Overall, 246 references were identified. Includ-
ed in this report are two publications on the clinical EORTC 18071 trial:  
 One publication assessed the efficacy of adjuvant therapy with 
ipilimumab on all survival endpoints in patients with high-risk 
stage III CM after CLND [3]. 
 The other publication assessed secondary outcomes including 
health-related quality of life (HRQoL) of patients with adjuvant 
ipilimumab after complete resection of high-risk stage III CM [10]. 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of evidence was conducted based on the EUnetHTA internal 
validity for randomised controlled trials [1]. Evidence was assessed based on 
the adequate generation of the randomisation sequence, allocation conceal-
ment, blinding of patient and treating physician, selective outcome report-
ing and other aspects that may increase the risk of bias. Study quality details 
are reported in Table 6 of the Appendix. 
To evaluate the magnitude of clinically meaningful benefit that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [32]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [33]. Further details about the 
ESMO-MCBS are reported in Table 4. 
 
rehabilitation and 
follow-up treatment 
systematic literature 
search in 5 databases: 
234 hints 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity 
magnitude of clinically 
meaningful benefit 
assessed by the  
ESMO-MCBS  
 
Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous 
melanoma  
LBI-HTA | 2017 13 
7.1 Clinical efficacy and safety –  
phase III studies 
EORTC 18071 [3], a randomised double-blind phase III trial, was conducted 
to assess the efficacy of adjuvant therapy with the human monoclonal anti-
body ipilimumab on all survival endpoints in patients with high-risk stage 
III CM after CLND. 
A total of 951 patients were enrolled to receive either 10 mg/kg of ipili-
mumab administered intravenously every three weeks for four times (four 
doses) as induction therapy, then every 12 weeks for up to three years as 
maintenance therapy (n = 475) or placebo (n = 476). The randomisation 
was stratified according to disease stages (stage IIIA vs. stage IIIB vs. stage 
IIIC with one, two, or three positive nodes vs. stage IIIC with four or more 
positive nodes) and geographic regions (North America, Europe, or Austral-
ia). In order to detect a hazard ratio of 0.76 with a power of 85.0%, a total of 
491 deaths would be required. Until now, 506 events of distant metastases or 
death and 376 deaths have occurred (cut-off date 31 January 2016). 
Four patients in the ipilimumab group and two patients in the placebo 
group did not start the randomly assigned regimen. The main analyses of 
the efficacy endpoints include all patients who had undergone randomisa-
tion according to the intention-to-treat principle (ipilimumab group: n = 
475; placebo group: n = 476). The safety analyses were assessed in patients 
who had received at least one dose of randomly assigned regimen (n = 471 
and n = 474, respectively). Moreover, the overall median follow-up was 5.3 
years. Of 471 patients who started ipilimumab, 240 (51.0%) discontinued 
treatment due to a drug-related adverse event (AE), as compared with 22 of 
474 patients (4.6%) of the placebo group who discontinued treatment be-
cause of an AE. Overall, a total of 63 patients (13.4%) in the ipilimumab 
group and 143 patients (30.2%) in the placebo group completed the full 
treatment period of three years. 
Enrolled patients (~38% women and ~62% men) had a median age of 51.5 
years in either treatment group. According to the AJCC criteria, the majori-
ty of the patients had stage IIIB (~44%) melanoma in both treatment 
groups. Detailed patient characteristics with inclusion- and exclusion crite-
ria can be found in Table 5 of the Appendix. 
The primary endpoint of the EORTC 18071 trial was recurrence-free sur-
vival (RFS). Secondary outcomes comprised overall survival (OS), distant 
metastasis-free survival (DMFS), safety and HRQoL. 
 
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of ipilimumab on mortality? 
Because the number of patients with a follow-up of more than seven years 
was too small, the estimated median OS was either unreliable or not 
reached. The OS rate at five years was 65.4% (95% CI 60.8–69.6) in the 
ipilimumab group, as compared with 54.4% (95% CI 49.7–58.9) in the pla-
cebo group. Thus, the OS rate was statistically significantly improved in the 
EORTC 18071: 
randomised,  
double-blind 
phase III study 
10 mg/kg ipilimumab 
intravenously or placebo 
 
 
randomisation  
according to  
disease stages and  
geographic regions 
 
median follow-up 
duration: 5.3 years; 
AE-related drug 
discontinuation: 
51.0% ipilimumab group 
4.6% placebo group 
 
median age of 51.5 years 
primary endpoint: RFS; 
main secondary end-
points: OS, DMFS, 
safety, HRQoL 
 
median OS was not 
reached 
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ipilimumab group (hazard ratio for death from any cause, 0.72; 95.1% CI, 
0.58–0.88; p = 0.001). Table 2 represents the efficacy of ipilimumab. 
 
D0006: How does ipilimumab affect progression (or recurrence) of cutane-
ous melanoma? 
At the time of data cut-off the RFS rate at five years was 40.8% in the ipili-
mumab group, as compared with 30.3% in the placebo group (hazard ratio 
for recurrence or death, 0.76; 95% CI, 0.64–0.89; p < 0.001).  
 
D0005: How does ipilimumab affect symptoms and findings (severity, fre-
quency) of cutaneous melanoma? 
The rate of DMFS at five years was higher in the ipilimumab group than in 
the placebo group (48.3% vs. 38.9%; hazard ratio for distant metastasis or 
death, 0.76; 95.8% CI, 0.64–0.92; p = 0.002).  
 
D0011: What is the effect of ipilimumab on patients̕ body functions? 
Patients receiving ipilimumab showed negative effects on fatigue, insomnia 
and diarrhoea at week 10 during induction therapy, compared to patients 
who received a placebo [10]. 
 
D0012: What is the effect of ipilimumab on generic health-related quality of 
life? 
D0013: What is the effect of ipilimumab on disease-specific quality of life? 
Patients’ mean global health scores during (77.32 [SD 17.36] vs. 72.96 
[17.82]; p = 0.00011) and after induction therapy (76.48 [17.52] vs. 72.32 
[18.60]; p = 0.00067) were statistically significantly different between the 
treatment groups, but were not defined as clinically relevant (10 points or 
more). However, differences in the mean HRQoL score were clinically rele-
vant at week 10 and showed worse HRQoL scores for diarrhoea (7.67 [17.05] 
vs. 18.17 [28.25]) and for insomnia (15.17 [22.53] vs. 25.60 [29.19]) for the 
patients receiving ipilimumab. Overall, HRQoL measured by the EORTC 
QLQ-C30 was similar between the treatment groups, as no clinically rele-
vant differences in global health status scores were observed during or after 
induction of therapy [10]. 
 
 
 
 
 
 
 
 
 
statistically significant 
improvement of the 5-
year RFS rate  
 
improved DMFS at 5 
years  
deterioration in fatigue, 
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difference in global 
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the treatment groups 
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Table 2: Efficacy results of EORTC 18071 trial  
Descriptive statistics and 
estimate variability  
(data cut-off 31st January 
2016) 
Treatment group Ipilimumab Placebo 
Number of subjects 475 476 
Median OS, months NA NA 
OS rate at 5 years, %, (95% CI) 65.4 (60.8–69.6) 54.4 (49.7–58.9) 
Median PFS, months NA NA 
RFS rate at 5 years,% 40.8 30.3 
DMFS rate at 5 years, % 48.3 38.9 
HRQoL, global health scores dur-
ing induction therapy, (SD) 77.32 (17.36) 72.96 (17.82) 
HRQoL, global health scores after 
induction therapy, (SD) 76.48 (17.52) 72.32 (18.60) 
Effect estimate per com-
parison 
Comparison groups Ipilimumab vs. placebo 
OS rate at 5 years 
HR 0.72 
95.1% CI 0.58–0.88 
Two-sided log-rank test 
p value 
p = 0.001 
RFS rate at 5 years 
HR 0.76 
95% CI 0.64–0.89 
Two-sided log-rank test 
p value p < 0.001 
DMFS rate at 5 years 
HR 0.76 
95.8% CI 0.64–0.92 
Two-sided log-rank test 
p value 
p = 0.002 
HRQoL during induction therapy 
Two-sided log-rank test 
p value p = 0.00011 
HRQoL after induction therapy 
Two-sided log-rank test 
p value p = 0.00067 
Abbreviations: CI = confidence interval, DMFS = distant metastatic-free survival, HR = hazard ratio, HRQoL = health-related quality of 
life, NA = not applicable, OS = overall survival, PFS = progression-free survival, RFS = recurrence-free survival, SD = standard devia-
tion 
 
7.1.2 Safety 
C0008: How safe is ipilimumab in relation to the comparator(s)? 
471 patients in the ipilimumab group and 474 patients in the placebo group 
were included in the safety population. AEs of any grade occurred in 465 pa-
tients (98.7%) of the ipilimumab group, with grade ≥3 AEs occurring in 225 
patients (54.1%). In contrast, 432 patients (91.1%) of the placebo group had 
an AE of any grade, with grade ≥3 AEs occurring in 124 patients (26.2%). In 
fact, immune-related AEs of grade ≥3 occurred in 41.6% and in 2.7% of the 
patients, respectively. In the ipilimumab group the most common grade ≥3 
immune-related AEs were gastrointestinal (16.8%), hepatic (10.9%) and en-
docrine (7.8%). Five patients (1.1%) died due to ipilimumab-induced AEs 
grade ≥3 immune-
related AEs in 41.6% 
most commonly 
including: 
gastrointestinal (16.8%) 
hepatic (10.9%) 
endocrine (7.8%) 
 
5 AE-related deaths 
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before the start of the maintenance therapy. Three of these five patients died 
from colitis (two with intestinal perforation), one patient from myocarditis 
and one patient from multi-organ failure associated with the Guillain-Barré-
Syndrome. All treatment-emergent AEs are illustrated in Table 3.  
 
C0002: Are the harms related to dosage or frequency of applying 
ipilimumab? 
In total, 251 of the 471 patients (53.3%) who started ipilimumab treatment 
discontinued treatment due to an AE. In 240 of the 471 patients (51.0%), the 
event was considered to be related to ipilimumab administration. In 
contrast, 22 of 474 patients (4.6%) of the placebo group discontinued 
treatment owing to an AE. Furthermore, 135 patients (28.7%) and 282 
patients (59.5%) in the ipilimumab group and in the placebo group, 
respectively, discontinued treatment because of disease recurrence. Overall, 
63 patients (13.4%) in the ipilimumab group and 143 (30.2%) in the placebo 
group completed the full three-year treatment period. 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of ipilimumab? 
Patients with an Eastern Cooperative Oncology Group (ECOG) perfor-
mance-status score of more than 1 indicating greater disability, an autoim-
mune disease, uncontrolled infection, substantial cardiovascular disease, a 
lactate dehydrogenase level of more than two times the upper limit of the 
normal range, and patients who made use of systemic glucocorticoids are 
more likely to be harmed through the administration of ipilimumab. Hence, 
these patients were excluded from the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53.3% of the patients 
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due to an AE; 
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Table 3: Most frequent adverse events 
 
Adverse event (according  
to CTCAE version 3.0) 
 
Ipilimumab (n = 471) Placebo (n = 474) 
 
Any grade 
n (%) 
Grade 3–4 
n (%) 
Grade 5 
n (%) 
Any grade 
n (%) 
Grade 3–4 
n (%) 
Grade 5 
n (%) 
Any immune-related adverse 
event 
426 (90.4) 196 (41.6) 5 (1.1) 188 (39.7) 13 (2.7) 0 
Any dermatological event 298 (63.3) 20 (4.2) 0 99 (20.9) 0 0 
     Rash 161 (34.2) 5 (1.1) 0 52 (11.0) 0 0 
Any gastrointestinal event 217 (46.1) 76 (16.2) 3 (0.6) 85 (17.9) 4 (0.8) 0 
     Diarrhoea 194 (41.2) 46 (9.8) 0 80 (16.9) 2 (0.4) 0 
     Colitis 73 (15.5) 36 (7.6) 3 (0.6) 7 (1.5) 2 (0.4) 0 
Any endocrine system event 178 (37.8) 37 (7.8) 0 38 (8.0) 1 (0.2) 0 
     Hypophysitis 77 (16.3) 21 (4.4) 0 1 (0.2) 0 0 
Any hepatic event 115 (24.4) 51 (10.9) 0 20 (4.2) 1 (0.2) 0 
     Increase in liver enzyme 
     levels 
83 (17.6) 20 (4.3) 0 18 (3.8) 0 0 
Any neurological event  21 (4.5) 9 (1.9) 0 9 (1.9) 0 0 
Other 111 (23.6) 36 (7.6) 2 (0.4) 23 (4.9) 8 (1.7) 0 
CTCAE = Common Terminology Criteria for Adverse Events 
 
 
7.2 Clinical effectiveness and safety –  
further studies 
No further study results on ipilimumab from phase II/III trials in the re-
viewed indication, including adjuvant therapy in patients with high-risk 
stage III CM after CLND, are available yet. 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of ipilimumab? 
Ipilimumab is available as 0.3, 3 and 10 mg/kg intravenous doses. At the 
recommended dose of 10 mg/kg every three weeks four times (four doses) 
(induction therapy), and thereafter every three months for up to three years 
(maintenance therapy), ipilimumab costs approximately € 62,264.30 per 21-
day cycle, assuming an average body weight of 70 kg. Therefore, the costs are 
€ 249,057.20 and € 435,850.10 for the induction therapy and for a one-year 
treatment cycle, respectively. 
 
no further study results 
of phase II/III trials 
available yet 
 
€ 62,264.30 per  
21-day cycle 
 
€ 435,850.10 per year 
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9 Ongoing research 
In March 2017 a search in the databases www.clinicaltrials.gov and 
www.chlinicaltrialsregister.com was conducted. The following three ongoing 
phase III trials are investigating ipilimumab in patients with high-risk stage 
III melanoma after CLND: 
 NCT02506153: A randomised phase III clinical trial is comparing 
high-dose recombinant interferon alfa-2B or ipilimumab to pem-
brolizumab in high risk patients with stage III-IV melanoma that 
has been removed by surgery. Estimated primary completion date 
is June 2020. 
 
 NCT02388906: A randomised, placebo-controlled, double-blind 
phase III study is comparing nivolumab to ipilimumab in high risk 
patients with stage IIIB/C-IV melanoma that has been removed by 
surgery. Estimated primary completion date is November 2018 [34]. 
 
 NCT01274338: A randomised phase III trial is comparing ipili-
mumab to high-dose interferon alfa-2b in treating high risk pa-
tients with stage III-IV melanoma that has been removed by sur-
gery. Estimated primary completion date is May 2018 [35]. 
 
Currently, five additional studies are ongoing in different treatment lines 
and regimens in patients after complete resection with stage IIIB/C or stage 
IV melanoma (NCT03068455, NCT02599402, NCT02905266, 
NCT02278887, NCT02224781). Besides, ipilimumab is also being investi-
gated for other indications like non-small cell lung cancer (NSCLC), squa-
mous cell lung cancer, stomach cancer, renal cell cancer, urothelial cancer 
and squamous cell carcinoma of the head and neck. 
 
 
 
10 Discussion 
In March 2011 the anti-CTLA-4 receptor ipilimumab was approved by the 
FDA and by the EMA for the treatment of unresectable or late-stage (meta-
static) melanoma in adults who have received prior therapy [9, 11]. For the 
adjuvant treatment in patients with high-risk stage III melanoma, ipili-
mumab is only approved in the U.S. (October 2015), but not yet in Europe 
[9].  
3 ongoing phase III 
studies are investigating 
ipilimumab in patients 
with high-risk stage III 
melanoma after CLND 
5 ongoing phase III 
studies in different 
treatment lines and 
regimes 
 
ipilimumab investigated 
in other indications 
2015: U.S. approval for 
adjuvant treatment in 
high-risk stage III 
melanoma  
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The randomised, double-blind, phase III study EORTC 18071 was aimed to 
assess the efficacy of adjuvant therapy with the human monoclonal antibody 
ipilimumab on all survival endpoints in patients with high-risk stage III CM 
after CLND. Owing to the fact that the number of patients with a follow-up 
of more than seven years was too small, the estimated median OS was either 
unreliable or not reached. Additionally, no data on PFS were available. 
However, ipilimumab monotherapy showed a significant improvement in 
the primary endpoint, the RFS rate at five years by 10.5% compared to the 
placebo group (hazard ratio for recurrence or death, 0.76; 95% CI, 0.64–0.89; 
p < 0.001). Moreover, the OS rate and the rate of DMFS at five years both 
statistically significantly improved by 11.0% and 9.4%, respectively, in the 
ipilimumab group (hazard ratio for death from any cause, 0.72; 95.1% CI, 
0.58–0.88; p = 0.001, and hazard ratio for distant metastases or death, 0.76; 
95.8% CI, 0.64–0.92; p = 0.002, respectively). In total, 240 of the 471 patients 
(51.0%) discontinued treatment due to an ipilimumab-induced adverse 
event. Furthermore, global HRQoL measured by the EORTC QLQ-C30 was 
similar between the two treatment groups, as no clinically relevant differ-
ences in global health status scores were observed during or after the induc-
tion of ipilimumab treatment [10]. However, the validity of these scores 
might be weak owing to the high discontinuation rate in the study. In fact, 
compliance with completing the HRQoL questionnaire was 893 (94.0%) of 
951 patients at baseline, 693 (75.0%) of 924 at week 24, and 354 (51.0%) of 
697 at week 108. 
Regarding the safety outcomes, 465 patients (98.7%) who received ipili-
mumab had all grade AEs, with grade ≥3 AEs occurring in 225 patients 
(54.1%). In contrast, 432 patients (91.1%) of the placebo group had an AE of 
any grade, with grade ≥3 AEs occurring in 124 patients (26.2%). In fact, 
there was a difference of 40.0% in grade ≥3 immune-related AEs between 
the treatment groups, including gastrointestinal (16.8% ipilimumab group 
vs. 0.8% placebo group), hepatic (10.9% vs. 0.2%) and endocrine (7.8% vs. 
0.2) AEs. Additionally, five patients (1.1%) died due to ipilimumab-induced 
AEs before the start of the maintenance therapy. 
In general, the study had a low risk of bias according to the assessment of 
the methodological quality of evidence based on the EUnetHTA internal va-
lidity for randomised controlled trials, as the allocation concealment was ad-
equate, the study was double-blinded, and selective outcome reporting was 
unlikely.  
Given the adjuvant therapy setting of ipilimumab, we applied Form 1 of the 
ESMO-MCBS in order to assess whether ipilimumab satisfies the criteria 
for a “meaningful clinical benefit” (score A or B). Both the original as well 
as the adapted version of the MCBS were applied [32, 33]. Because the end-
points disease-free survival (DFS) and RFS do not differ in their definitions, 
we used the primary endpoint RFS to generate a score. The application of 
the ESMO-MCBS to the EORTC 18071 study resulted in a grade A and C in 
the original and the adapted version of the ESMO-MCBS, respectively. 
Therefore, ipilimumab only leads to a meaningful clinical benefit in the 
original scale, but not in the adapted framework. This difference occurs due 
to the use of the point estimate of the HR and the higher implication of tox-
icities in the adapted ESMO-MCBS. 
no OS and PFS data 
available 
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Various studies have shown that immune therapies, especially ipilimumab, 
have been praised because of their improved impact on survival rates in ad-
vanced stages of melanoma, albeit at the cost of a higher frequency of toxic 
effects. Most commonly these effects include gastrointestinal disturbances, 
which in a few cases even led to death [36-39]. These findings were in line 
with the EORTC 18071 trial results presenting a difference in grade ≥3 
immune-related AEs of 40.0% and five drug-related deaths in the ipili-
mumab group. Nevertheless, Bouwhuis et al. showed that these autoimmun-
ity- and immune-related AEs were associated with response to ipilimumab 
and favourable outcomes [37]. However, the success of ipilimumab is de-
pendent partly on the patient’s immune system, as well as on his/her ability 
to generate an active, tumour-specific response. Additionally, psychological 
stress factors, such as financial-, familial-, and sleep-related problems, which 
are likely to occur after the diagnosis of melanoma, are known to alter hor-
mone levels and are deemed to affect both innate and adoptive immune re-
sponse pathways. Therefore, these factors need to be considered during the 
management of melanoma with immune-based drugs [36]. 
Given the fact that the half-life of ipilimumab is 15 days, a prolonged activi-
ty can be expected [40]. Indeed, Johnson et al. investigated chronic immune 
toxicities and health outcomes of long-term survivors who received ipili-
mumab approximately two years ago [39]. Few patients suffered from ipili-
mumab-associated chronic toxicities after two years of administration, in-
cluding colitis, hypophysitis, pruritus, skin rashes and neurological events 
(e.g., memory loss). Moreover, no other AEs like cardiac, pulmonary, renal, 
hematologic, neoplastic or hepatic events were observed in most of the pa-
tients. Overall, ipilimumab was associated with good functional outcomes in 
patients with extended survival with only a few exceptions [39]. Neverthe-
less, only a subset of melanoma patients with advanced or metastatic disease 
still seems to generally benefit from the therapy. Hence, predictive bi-
omarkers identifying these patients need to be investigated in order to fur-
ther improve response rates and outcomes, as well as to spare patients the 
increased risk of severe AEs [28, 37]. 
Long-term effects of ipilimumab have shown to be sound in most cases [39]. 
On top of ipilimumab, both high-dose interferon alpha-2b and pegylated in-
terferon alpha-2b have also demonstrated significantly improved relapse-
free-, disease-free- and overall survival in randomised clinical trials for ad-
juvant systemic therapy in high-risk CM [41]. Currently, an ongoing study 
(ECOG E-1609) is investigating ipilimumab compared to high-dose inter-
feron alfa-2b in treating patients with high-risk stage III-IV melanoma that 
have been removed by surgery [35]. These results should give further impli-
cations about which therapy patients benefit the most, since ipilimumab is 
only compared to placebo and not to the standard therapy, interferon alpha, 
in this indication. Furthermore, combining CTLA-4 receptors and PD-1 
blockades could result in increased anti-tumour activity compared to either 
strategy alone. In fact, the combination of ipilimumab and nivolumab in-
creased the degree of tumour response and was associated with greater num-
bers of effector T cells of CM. The results from two studies, Checkmate-067 
and -069, confirmed this, however, at the cost of clearly increased severe 
treatment-related AEs. Therefore, once more predictive biomarkers will 
likely be needed to identify patients who will require combination treatment 
regimens despite the higher toxicity rates in order to maximise anti-tumour 
responses [28]. Moreover, several ongoing studies are investigating ipili-
mumab in combination with radiotherapy for melanoma, as there might be a 
improved efficacy of 
ipilimumab at the cost 
of higher toxicity profile 
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synergy of cancer immunotherapy and radiotherapy [42]. Therefore, ongoing 
studies remain to be seen in order to possess comparable results. 
One of the biggest hurdles of immune-based therapies is the cost [36]. At the 
recommended dose of 10 mg/kg every three weeks for four times (four doses) 
(induction therapy) and thereafter every three months for up to three years 
(maintenance therapy), ipilimumab costs approximately € 435,850.10 per 
year (induction: € 249,057.20 + maintenance: € 186,792.90). Moreover, the 
high percentage of severe immune-related AEs, as well as long-term conse-
quences due to ipilimumab administration, lead to additional costs in the 
present, as well as in the future. Therefore, it is crucial to make immune 
therapies like ipilimumab more affordable by decreasing the costs of im-
mune-based treatment approaches [36, 39].  
Overall, even if the administration of ipilimumab increases the rate of toxic-
ities, no statistically significant differences in HRQoL between the treat-
ment groups have been investigated. However, these results should be seen 
with caution because of the high discontinuation rate. In fact, ipilimumab 
statistically significantly improved the RFS rate by 10.5% compared to the 
placebo group. Additionally, the OS rate and the rate of DMFS at five years 
statistically significantly increased. In long-term survivors, too, ipilimumab 
was associated with good functional outcomes with only a few exceptions. 
Nevertheless, the identification of predictive biomarkers may be crucial in 
order to further improve response rates and outcomes, and to reduce severe 
AEs. In addition, ongoing studies remain to be seen in order to possess com-
parable results. Finally, the costs of the immune therapies are a big hurdle, 
partly because AEs and long-term consequences can lead to additional costs. 
Hence, aiming for a reduction of immune therapy costs (annual ipilimumab 
therapy costs: € 435,850.10) may be a crucial step in the near future. 
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Table 4: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [34, 35] 
Abbreviations: AJ = Adjustments, CM = cutaneous melanoma, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, ND = no difference, PE = primary endpoint, PM = 
preliminary magnitude of clinical benefit grade, QoL = quality of life, RFS = recurrence-free survival 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
 
 
 
 
 
                                                             
1
 One level downgrade because >10% grade ≥3 adverse events.   
ESMO-
MCBS 
Active sub-
stance 
Indication Intention PE Form 
Efficacy Safety 
AJ FM 
RFS rate 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
adapted 
ESMO-
MCBS 
ipilimumab stage III CM adjuvant 
therapy 
RFS 1 intervention: 40.8% 
control: 30.3% 
0.76 
0.64-0.89 
improvement in RFS alone: 
HR 0.65–0.80, without ma-
ture OS data 
B 
+86.7% grade  
3–4 AEs (-1)1 
ND -1 C 
ESMO-
MCBS ipilimumab stage III CM 
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control: 30.3% 
0.76 
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Table 5: Characteristics of EORTC 18071 trial 
Title: Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy 
Study identifier NCT00636168, EudraCT 2007-001974-10, EORTC 18071 
Design 
Randomised, double-blind, multinational, phase III trial 
Duration of main phase: 
10 July 2008 to 1 August 2011 + median follow-up of 5.3 
years 
Duration of Run-in phase: NA 
Duration of Extension phase: NA 
Hypothesis 
Superiority 
The study was designed to assess the efficacy of adjuvant therapy with the human monoclonal an-
tibody ipilimumab on all survival endpoints in patients with high-risk stage III CM after CLND. Pre-
specified criteria for superiority required a total of 491 deaths in order to detect a hazard ratio of 
0.76 with a power of 85.0%. 
Funding Bristol-Myers Squibb 
Treatments groups 
Ipilimumab group (n = 475) 10 mg/kg (intravenously) every three weeks for four dos-
es, then every 12 weeks of up to three years 
Placebo group (n = 476) 10 mg/kg (intravenously) every three weeks for four dos-es, then every 12 weeks of up to three years 
Endpoints and definitions 
Recurrence-free 
survival  RFS 
The time from randomisation until the date of first recur-
rence (local, regional or distant metastasis) or death from 
any cause 
Overall survival OS The time from randomisation until death from any cause 
Distant metasta-
sis-free survival 
DMFS The time from randomisation until the date of the first 
distant metastasis or death from any cause 
Health-related 
quality of life 
HRQoL - 
Database lock Last verified: June 2016 
Results and analysis  
Analysis description Primary Analysis 
Data were collected and computerised at the EORTC headquarters. The trial was conducted in ac-
cordance with the Declaration of Helsinki and with Good Clinical Practice guidelines as defined by 
the International Conference on Harmonisation. All patients provided written informed consent. A 
total of 491 deaths were required in order to provide the trial with 85.0% power to detect a supe-
riority of ipilimumab, corresponding to a hazard ratio for death of 0.76. Efficacy analyses (primary 
and secondary endpoints) were performed in the intention-to-treat population, which was defined 
as all randomly assigned patients. The safety profile was assessed in patients who have received at 
least one dose of the randomly assigned regimen. Given the 506 events of distant metastasis or 
death and 376 deaths at the clinical cut-off date, it was computed (with the use of a Lan-DeMets 
Alpha-Spending Function) that the final analyses of OS and DMFS is performed at two-sided alpha 
levels of 0.049 and 0.042, respectively, so the confidence interval for the hazard ratio of the group 
comparison regarding these endpoints was set at 95.1% and 95.8%, respectively; the statistical 
power was 75.8% and 89.4%, respectively. 
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Title: Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy 
Study identifier NCT00636168, EudraCT 2007-001974-10, EORTC 18071 
Analysis population Inclusion  minimum age of 18 years 
 histologically confirmed CM that was metastatic to re-
gional lymph nodes 
 stage IIIA melanoma according to AJCC 2009 classifica-
tion 
 patients with N1a cancer need at least one metastasis 
measuring >1 mm in the greatest dimension 
 stage IIIB or IIIC CM with no in-transit metastases ac-
cording to AJCC 2009 classification 
 complete regional lymphadenectomy within 12 weeks 
before randomisation 
Exclusion 
 ECOG performance-status score of more than 1 
 autoimmune disease 
 uncontrolled infection 
 substantial cardiovascular disease (New York Heart As-
sociation functional class III or IV) 
 lactate dehydrogenase level of more than two times 
the upper limit of the normal range 
 use of systemic glucocorticoids 
 previous systemic therapy for CM 
Characteristics Ipilimumab Placebo 
Sex, no. (%)   
     Male 296 (62.3) 293 (61.6) 
     Female 179 (37.7) 183 (38.4) 
Median age, years (range) 51 (20-84) 52 (18-78) 
Distribution, no (%)   
     <50 years 214 (45.1) 211 (44.3) 
     51 to <65 years 180 (37.9) 178 (37.4) 
     ≥65 years 81 (17.1) 87 (18.3) 
Disease stage, no. (%)   
  At randomisation   
     IIIA 98 (20.6) 88 (18.5) 
     IIIB 182 (38.3) 182 (38.2) 
     IIIC with 1-3 positive lymph 
     nodes 122 (25.7) 121 (25.4) 
     IIIC with ≥4 positive lymph  
     nodes 
73 (15.4) 75 (15.8) 
  According to AJCC 2002  
  criteria   
     IIIA 98 (20.6) 88 (18.5) 
     IIIB 213 (44.8) 207 (43.5) 
     IIIC with 1-3 positive lymph  
     nodes 69 (14.5) 83 (17.4) 
     IIIC with ≥4 positive lymph  
     nodes 
95 (20.0) 98 (20.6) 
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Title: Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy 
Study identifier NCT00636168, EudraCT 2007-001974-10, EORTC 18071 
Type of lymph-node involve-
ment, no. (%)   
     Microscopic 210 (44.2) 193 (40.5) 
     Macroscopic 265 (55.8) 283 (59.5) 
No. of positive lymph nodes 
on pathological testing, no. 
(%) 
  
     1 217 (45.7) 220 (46.2) 
     2 or 3 163 (34.3) 158 (33.2) 
     ≥4 95 (20.0) 98 (20.6) 
Ulceration, no. (%)   
     Yes 197 (41.5) 203 (42.6) 
     No 257 (54.1) 244 (51.3) 
     Unknown 21 (4.4) 29 (6.1) 
Abbreviations: AJCC = American Joint Committee on Cancer, CLND = complete lymph node dissection, CM = cutaneous melanoma, DMFS = 
distant metastasis-free survival, ECOG = Eastern Cooperative Oncology Group, HRQoL = health-related quality of life, OS = overall survival, RFS 
= recurrence-free survival 
 
 
Table 6: Risk of bias assessment on study level based on EUnetHTA (Internal validity of randomised controlled tri-
als) [43] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: randomisation stratified according to dis-
ease stages and geographic regions 
unclear 
Adequate allocation concealment: centrally interactive voice-response system yes 
Blinding:  
double-blinded 
Patient yes 
Treating physician yes 
Selective outcome reporting unlikely yes 
No other aspects which increase the risk of bias: industry funded no 
Risk of bias – study level low 
 
